ECSP045275A - Derivados de tiazol y oxazol que modulan la actividad de ppar - Google Patents

Derivados de tiazol y oxazol que modulan la actividad de ppar

Info

Publication number
ECSP045275A
ECSP045275A EC2004005275A ECSP045275A ECSP045275A EC SP045275 A ECSP045275 A EC SP045275A EC 2004005275 A EC2004005275 A EC 2004005275A EC SP045275 A ECSP045275 A EC SP045275A EC SP045275 A ECSP045275 A EC SP045275A
Authority
EC
Ecuador
Prior art keywords
ppar
activity
compounds
tiazol
oxazol
Prior art date
Application number
EC2004005275A
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ECSP045275A publication Critical patent/ECSP045275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta invención describe compuestos que alteran la actividad de PPAR. La invención también describe sales farmacéuticamente aceptables de los compuestos, composiciones farmacéuticamente aceptables que comprenden los compuestos o sus sales, y métodos para utilizarlas como agentes terapéuticos para tratar o prevenir hiperlipidemia e hipercolesteremia en un mamífero. La presente invención también describe un método para obtener los compuestos descritos.
EC2004005275A 2002-03-07 2004-09-24 Derivados de tiazol y oxazol que modulan la actividad de ppar ECSP045275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
ECSP045275A true ECSP045275A (es) 2004-10-26

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005275A ECSP045275A (es) 2002-03-07 2004-09-24 Derivados de tiazol y oxazol que modulan la actividad de ppar

Country Status (29)

Country Link
US (1) US6833380B2 (es)
EP (1) EP1485091A1 (es)
JP (1) JP2005524665A (es)
KR (1) KR20040091694A (es)
CN (1) CN1638768A (es)
AP (1) AP2004003123A0 (es)
AR (1) AR038883A1 (es)
AU (1) AU2003207891A1 (es)
BR (1) BR0308221A (es)
CA (1) CA2476580A1 (es)
CO (1) CO5601013A2 (es)
EA (1) EA200401160A1 (es)
EC (1) ECSP045275A (es)
GT (1) GT200300053A (es)
HR (1) HRP20040810A2 (es)
IL (1) IL163768A0 (es)
IS (1) IS7399A (es)
MA (1) MA27182A1 (es)
MX (1) MXPA04008624A (es)
NO (1) NO20044245L (es)
OA (1) OA12781A (es)
PA (1) PA8568701A1 (es)
PE (1) PE20031010A1 (es)
PL (1) PL372971A1 (es)
TN (1) TNSN04167A1 (es)
TW (1) TW200400027A (es)
UY (1) UY27704A1 (es)
WO (1) WO2003074052A1 (es)
ZA (1) ZA200406491B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
AU2006265172B2 (en) 2005-06-30 2011-09-15 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
ES2409215T3 (es) 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2637794T3 (es) 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
EE03765B1 (et) 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
AU7073400A (en) 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
US6930120B2 (en) 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
HUP0400023A2 (hu) 2001-05-29 2004-04-28 Kyoto Pharmaceutical Industries, Ltd. Új heterociklusos származékok és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
PL367077A1 (en) 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
WO2002102780A1 (en) 2001-06-18 2002-12-27 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
US6869975B2 (en) 2001-09-14 2005-03-22 Tularik Inc. Linked biaryl compounds
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
HRP20040810A2 (en) 2004-12-31
MA27182A1 (fr) 2005-01-03
PA8568701A1 (es) 2003-11-12
NO20044245L (no) 2004-10-06
IS7399A (is) 2004-08-12
ZA200406491B (en) 2006-05-31
US6833380B2 (en) 2004-12-21
PL372971A1 (en) 2005-08-08
PE20031010A1 (es) 2003-12-12
JP2005524665A (ja) 2005-08-18
OA12781A (en) 2006-07-07
BR0308221A (pt) 2005-01-04
CA2476580A1 (en) 2003-09-12
CN1638768A (zh) 2005-07-13
CO5601013A2 (es) 2006-01-31
EA200401160A1 (ru) 2005-02-24
WO2003074052A1 (en) 2003-09-12
MXPA04008624A (es) 2004-12-06
TW200400027A (en) 2004-01-01
TNSN04167A1 (fr) 2007-03-12
US20030207916A1 (en) 2003-11-06
AP2004003123A0 (en) 2004-09-30
KR20040091694A (ko) 2004-10-28
GT200300053A (es) 2003-10-10
AU2003207891A1 (en) 2003-09-16
UY27704A1 (es) 2003-10-31
EP1485091A1 (en) 2004-12-15
AR038883A1 (es) 2005-02-02
IL163768A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
ECSP045275A (es) Derivados de tiazol y oxazol que modulan la actividad de ppar
UY27696A1 (es) Compuestos que modulan la actividad de ppar
ECSP045285A (es) Compuestos que modulan la actividad de ppar
DOP2003000620A (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparación
DOP2004000881A (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
UY39188A (es) Imidazopiridazinas como moduladores de il-17
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
MX382184B (es) Cisteamina recubierta entericamente, cistamina y derivados de ellas.
PA8680701A1 (es) Derivados de oxindol
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
ECSP088352A (es) Derivados de indol 1,3-disustituido para su uso como moduladores de ppar
DOP2006000193A (es) Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso
ECSP077270A (es) Ácidos de tiazolo - naftilo
CR10600A (es) Ciclopenta (d) pirimidinas hidroxiladas y metoxiladas como inhibidores de akt proteina quinasa
SV2010003567A (es) Derivados bis-(sulfonilamino) en terapia 066
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
BRMU8400812Y1 (pt) aperfeiçoamento introduzido em fonte de luz para tratamento da hiperbilirrubinemia por fototerapia.
CR9903A (es) Compuestos antihipercolesterolemicos
UY30460A1 (es) Compuestos terapéuticos
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso